Teltow / Leipzig, December 08, 2021 – As part of his inauguration, His Excellency, Mr. Francisco Quiroga, Ambassador of the United States of Mexico to Germany, accompanied by the Honorary Consul of the United States of Mexico in Saxony, Dr. Joachim Lamla, as well as Oliver Contla, head of the economic department of the Mexican embassy and Florentino Cabrera, head of the tourism promotion department, the city of Leipzig and the BIO CITY. Here they gained an insight into various companies represented at the site, including CO.DON AG.
Mr. Bur, member of the board of the company, introduced the company and gave an insight into the production plant for the manufacture of the EU-wide approved drug during a guided tour. The politicians were impressed by the innovative process and the production laboratories of CO.DON AG.
The Executive Board of CO.DON AG sees great potential for the innovative therapy options in North America as part of the company's non-European licensing activities. After the USA, Mexico is the most important and most diversified industrial location in the American economic area. Bauerfeind AG, CO.DON AG's anchor investor, has been successfully active here for several years.
CO.DON AG develops, produces and sells endogenous cell therapies for the minimally invasive repair of cartilage defects. The drug offered is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint using only the body's own cartilage cells. The method offered by CO.DON is currently used in over 200 clinics in Germany and has already been used in over 17.000 patients. In July 2017, CO.DON received EU-wide approval for this drug, and in March 2019 approval for Switzerland. At the Leipzig site, CO.DON built one of the largest plants for the production of human cells on an industrial scale for in-house and contract production. The shares of CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A3E5C08). Board of Directors of the company: Tilmann Bur, Dr. Achim Simons.
Director of Corporate Communications
Investor Relations/Public Relations
T: + 49 (0) 341 99190 330
F: +49 (0) 341 99190 309
Source: Press Release www.codon.de by 08.12.2021